Atrial Fibrillation in Heart Failure

Medical Clinics of North America

Volumn 96, Issue 5, 2012, Pages 987-1000

  Lardizabal, Joel A ^a   Deedwania, Prakash C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antiarrhythmic therapy; Antithrombotic therapy; Atrial fibrillation; Catheter ablation; Heart failure; Prognosis; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BISOPROLOL; CARVEDILOL; CLOPIDOGREL; DABIGATRAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DRONEDARONE; IRBESARTAN; IVABRADINE; METOPROLOL; METOPROLOL SUCCINATE; PLACEBO; RANOLAZINE; WARFARIN;

ANTICOAGULANT THERAPY; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COX MAZE PROCEDURE; DISEASE SEVERITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; EXERCISE; FOLLOW UP; HEALTH CARE COST; HEART ARRHYTHMIA; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART EJECTION FRACTION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REFRACTORY PERIOD; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE FILLING; HEART VENTRICLE FUNCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MINIMALLY INVASIVE PROCEDURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PULMONARY VEIN ISOLATION; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; SINUS NODE; SINUS RHYTHM; SURGICAL TECHNIQUE; SURVIVAL; TACHYCARDIA; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; UNITED STATES;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HEART FAILURE; HEART RATE; HUMANS; PROGNOSIS;

EID: 84866170323     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.07.007     Document Type: Review

References (61)

1. National Heart, Lung, and Blood Institute NHLBI Fiscal Year 2009 Factbook 2009, National Institutes of Health, Maryland (US).
2. American Heart Association Heart Disease, Stroke Statistics Writing Group Executive summary: heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123(4):459-463.
3. Lloyd-Jones D., Larson M., Leip E., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002, 106:3068.
4. Cleland J.G., Swedberg K., Follath F., et al. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003, 24:442-463.
5. Benjamin E.J., Levy D., Vaziri S.M., et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994, 271(11):840-844.
6. Deedwania P.C., Lardizabal J.A. Atrial fibrillation in heart failure: a comprehensive review. Am J Med 2010, 123(3):198-204.
7. Pozzoli M., Cioffi G., Traversi E., et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998, 32(1):197-204.
8. Dries D.L., Exner D.V., Gersh B.J., et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998, 32(3):695-703.
9. Olsson L.G., Swedberg K., Ducharme A., et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006, 47(10):1997-2004.
10. Mamas M.A., Caldwell J.C., Chacko S., et al. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 2009, 11(7):676-683.
11. Carson P.E., Johnson G.R., Dunkman W.B., et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993, 87(Suppl 6):VI102-VI110.
12. Crijns H.J., Tjeerdsma G., de Kam P.J., et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000, 21(15):1238-1245.
13. Swedberg K., Olsson L.G., Charlesworth A., et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 2005, 26(13):1303-1308.
14. Leonard J.J., Shaver J., Thompson M. Left atrial transport function. Trans Am Clin Climatol Assoc 1981, 92:133-141.
15. Rahimtoola S.H., Ehsani A., Sinno M.Z., et al. Left atrial transport function in myocardial infarction. Importance of its booster pump function. Am J Med 1975, 59(5):686-694.
16. Raymond R.J., Lee A.J., Messineo F.C., et al. Cardiac performance early after cardioversion from atrial fibrillation. Am Heart J 1998, 136(3):435-442.
17. Shite J., Yokota Y., Yokoyama M. Heterogeneity and time course of improvement in cardiac function after cardioversion of chronic atrial fibrillation: assessment of serial echocardiographic indices. Br Heart J 1993, 70(2):154-159.
18. Pardaens K., Van Cleemput J., Vanhaecke J., et al. Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart 1997, 78:564-568.
19. Clark D.M., Plumb V.J., Epstein A.E., et al. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997, 30(4):1039-1045.
20. Shinbane J.S., Wood M.A., Jensen D.N., et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997, 29(4):709-715.
21. Byrne M.J., Raman J.S., Alferness C.A., et al. An ovine model of tachycardia-induced degenerative dilated cardiomyopathy and heart failure with prolonged onset. J Card Fail 2002, 8(2):108-115.
22. Nerheim P., Birger-Botkin S., Piracha L., et al. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 2004, 110:247-252.
23. Solti F., Vecsey T., Kékesi V., et al. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res 1989, 23(10):882-886.
24. Eijsbouts S.C., Majidi M., van Zandvoort M., et al. Effects of acute atrial dilation on heterogeneity in conduction in the isolated rabbit heart. J Cardiovasc Electrophysiol 2003, 14:269-278.
25. Boyden P.A., Tilley L.P., Albala A., et al. Mechanisms for atrial arrhythmias associated with cardiomyopathy: a study of feline hearts with primary myocardial disease. Circulation 1984, 69:1036-1047.
26. Ng J., Villuendas R., Cokic I., et al. Autonomic remodeling in the left atrium and pulmonary veins in heart failure-creation of a dynamic substrate for atrial fibrillation. Circ Arrhythm Electrophysiol 2011, 4(3):388-396.
27. Li D., Shinagawa K., Pang L., et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001, 104:2608.
28. Yeh Y., Wakili R., Qi X., et al. Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol 2008, 1:93-102.
29. Deedwania P.C., Singh B.N., Ellenbogen K., et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). Circulation 1998, 98(23):2574-2579.
30. Hagens V.E., Crijns H.J., Van Veldhuisen D.J., et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J 2005, 149(6):1106-1111.
31. Pedersen O.D., Bagger H., Keller N., et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (DIAMOND) substudy. Circulation 2001, 104(3):292-296.
32. Shelton R.J., Clark A.L., Goode K., et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure (CAFE-II). Heart 2009, 95(11):924-930.
33. Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008, 358(25):2667-2677.
34. Domanski M.J., Krause-Steinrauf H., Massie B.M., et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail 2003, 9(5):354-363.
35. Fuster V., Rydén L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2006, 114(7):e257-e354.
36. Van Gelder I.C., Groenveld H.F., Crijns H.J., et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010, 362(15):1363-1373.
37. Lechat P., Escolano S., Golmard J.L., et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1997, 96:2197-2205.
38. Metra M., Torp-Pedersen C., Swedberg K., et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 2005, 26(21):2259-2268.
39. Fox K., Ford I., Steg P.G., et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008, 372(9641):817-821.
40. Swedberg K., Komajda M., Böhm M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376(9744):875-885.
41. Olgin J.E., Scheinman M.M. Comparison of high energy direct current and radiofrequency catheter ablation of the atrioventricular junction. J Am Coll Cardiol 1993, 21(3):557-564.
42. Williamson B.D., Man K.C., Daoud E., et al. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med 1994, 331(14):910-917.
43. Dong K., Shen W.K., Powell B.D., et al. Atrioventricular nodal ablation predicts survival benefit in patients with atrial fibrillation receiving cardiac resynchronization therapy. Heart Rhythm 2010, 7(9):1240-1245.
44. Lardizabal J.A., Huang G., Deedwania P.C. Modern pharmacologic strategies in the management of atrial fibrillation. J Innov Card Rhythm Management 2011, 2:1-9.
45. Køber L., Torp-Pedersen C., McMurray J.J., et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008, 358(25):2678-2687.
46. ATHENA Investigators Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009, 360(7):668-678.
47. Gaynor S.L., Schuessler R.B., Bailey M.S., et al. Surgical treatment of atrial fibrillation: predictors of late recurrence. J Thorac Cardiovasc Surg 2005, 129(1):104-111.
48. Ad N., Henry L., Hunt S. The impact of surgical ablation in patients with low ejection fraction, heart failure, and atrial fibrillation. Eur J Cardiothorac Surg 2011, 40(1):70-76.
49. Cui Y.Q., Sun L.B., Li Y., et al. Intraoperative modified Cox mini-maze procedure for long-standing persistent atrial fibrillation. Ann Thorac Surg 2008, 85(4):1283-1289.
50. Khan M.N., Jaïs P., Cummings J., et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008, 359(17):1778-1785.
51. Wann L.S., Curtis A.B., January C.T., et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011, 57(2):223-242.
52. Deedwania P.C., Lardizabal J.A. Non-antiarrhythmic therapies. Electrophysiological disorders of the heart 2011, 82-83. Churchill-Livingstone, Oxford (UK). 2nd edition. S. Saksena, C. John (Eds.).
53. Zhang L., Zhang S., Jiang H., et al. Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials. Clin Cardiol 2011, 34(2):117-123.
54. Nodari S., Triggiani M., Campia U., et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 2011, 57(7):870-879.
55. Rastogi S., Sharov V.G., Mishra S., et al. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol 2008, 295(5):H2149-H2155.
56. Schneider M.P., Hua T.A., Böhm M., et al. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010, 55(21):2299-2307.
57. ACTIVE-I Investigators Irbesartan in patients with atrial fibrillation. N Engl J Med 2011, 364(10):928-938.
58. Shammas F.V., Dickstein K. Clinical pharmacokinetics in heart failure: an updated review. Clin Pharmacokinet 1988, 15(2):94-113.
59. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361(12):1139-1151.
60. Wann L.S., Curtis A.B., Ellenbogen K.A., et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran). A Report of the American College of Cardiology Foundation Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011, 57(11):1330-1337.
61. Connolly S., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006, 367(9526):1903-1912.